Serina lines up $25M equity facility with Roth to fund drug pipeline
What's the deal? Serina Therapeutics has secured a $25 million equity financing facility through a Common Stock Purchase Agreement with Roth Principal Investments, LLC. Dated August 21, 2026, the deal lets Serina sell up to $25 million of newly issued common stock over a 36-month period — though it is under no obligation to do so.
How it works: Serina can direct Roth to buy shares at its discretion, through market open, intraday, pre-market, or post-market purchases. The price is set at a discount to the volume-weighted average price, ranging from 3% to 7% depending on the type and cumulative amount of purchases. Sales require the stock to trade above a set threshold.
What's the endgame? The facility gives Serina, a pharmaceutical company, a flexible source of capital for working capital and general corporate purposes. That liquidity is critical as it advances its drug pipeline.
What could go wrong? Selling shares at a discount can dilute existing shareholders. Issuances are capped at 5,077,554 shares — 19.99% of outstanding stock — unless stockholders approve more, and Roth's ownership is capped too.
What else? Serina has agreed not to issue additional shares until the resale registration statement is effective, with limited exceptions, and Roth has agreed not to engage in short selling. The company engaged Compass Point Research & Trading, LLC as a qualified independent underwriter for the related registration statement.
The signal: Equity facilities like this let small pharmaceutical companies draw down capital on demand rather than raising in a single, dilutive block. The structure trades certainty for flexibility — useful for a clinical-stage business managing cash against an unpredictable pipeline.
Read more: minichart.com.sg
Image credit: foteih
